Advertisements


This New Drug Combination Doubles the Chance of Keeping Lung Cancer at Bay

The finding could result in annual sales of $4.6 billion by 2023. Adding Roche’s rhhvf immunotherap.....»»

Category: europeSource: fortuneDec 7th, 2017

Roche drug cocktail doubles chance of halting lung cancer

Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented......»»

Category: topSource: foxnewsDec 7th, 2017

Roche drug cocktail doubles chance of holding lung cancer at bay

Roche's November announcement that its Impower 150 trial had broadly succeeded in first-line lung cancer patients.....»»

Category: topSource: business-standardDec 7th, 2017

BioLineRx Begins Trial on BL-8040/ Keytruda Combination

BioLineRx, Ltd. (BLRX) announced the initiation of a phase IIa trial on its lead oncology candidate, BL-8040, in combination with Merck & Co., Inc.???s (MRK) lung cancer drug Keytruda (pembrolizumab). BioLineRx, Ltd. BLRX announced the initiati.....»»

Category: topSource: zacksSep 21st, 2016

USFDA accepts Panacea Biotec"s ANDA for generic cancer drug

This product is a generic version of Abraxane, which is used for treatment of breast cancer, non-small lung cancer and adenocarcinoma of pancreas, it said......»»

Category: topSource: business-standardNov 30th, 2017

Incyte, AstraZeneca expand collaboration on potential lung cancer therapy

Incyte Corp. is expanding its clinical collaboration with MedImmune, AstraZeneca's global biologics research and development arm. As part of the expanded agreement, the two companies will evaluate the effectiveness and safety of a combination therapy.....»»

Category: topSource: bizjournalsOct 31st, 2017

Merck shares fall deeper into red as European lung-cancer marketing application pulled

Merck & Co. shares fell in the extended session Friday after the drug maker said it was no longer pursuing market approval for a lung cancer drug in Europe. Merck shares declined 2.3% to $56.91 after hours, adding to a 6.1% drop during Friday'.....»»

Category: topSource: marketwatchOct 27th, 2017

Biotech company aims to raise up to $22M in Austin"s next IPO; Cancer-fighting drug in advanced trials

Biotech IPOs have been pretty popular in Austin in recent years. The latest one comes from a company battling non-small cell lung cancer that intends to price its offering at $5 a share......»»

Category: topSource: bizjournalsOct 24th, 2017

Spectrum Pharma Investors Optimistic Over New Lung Cancer Drug

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) shares are trading higher by $7.20 (50 percent) at $21.66 in Wednesday's session. read more.....»»

Category: blogSource: benzingaOct 18th, 2017

Bristol-Myers Gets a Boost

The Checkmate-227 drug trial evaluating non-small cell lung cancer is raising sentiment......»»

Category: topSource: barronsOct 16th, 2017

Lilly"s (LLY) Verzenio Fails in Phase III Lung Cancer Study

Lilly's breast cancer drug, Verzenio, failed to achieve primary e.....»»

Category: personnelSource: nytOct 11th, 2017

Eli Lilly Shares Spike On Patent Victory

The U.S. Patent and Trademark Office ruled in favor of Eli Lilly and Co (NYSE: LLY) Thursday in an inter partes review of the ’209 patent for Alimta, a chemotherapy drug for lung cancer. read more.....»»

Category: blogSource: benzingaOct 5th, 2017

Pfizer Lung Cancer Drug"s Overall Survival Data Unfavorable

Pfizer (PFE) announced final ov.....»»

Category: worldSource: nytSep 12th, 2017

AstraZeneca"s Lung Cancer Study Data Promising, Shares Spike

AstraZeneca, (AZN) releases data from a late-stage study on Imfinzi which showed that the new cancer drug led to superior progression-free survival to standard of care in lung cancer patients. AstraZeneca, plc A.....»»

Category: worldSource: nytSep 11th, 2017

AstraZeneca shares tick higher on lung cancer drug study results

U.S. shares of AstraZeneca PLC rose in the extended session Friday after the drug maker released.....»»

Category: topSource: marketwatchSep 8th, 2017

Bristol-Myers Squibb says late-stage cancer drug combination study met endpoints and will be stopped early

Bristol-Myers Squibb Co. said early Thursday that a late-stage clinical trial for cancer drugs Opdivo and Yervoy in patients.....»»

Category: topSource: marketwatchSep 7th, 2017

Brainstorm Health: Vitamin B Cancer Risk, Merck’s Trump Boost, Novartis Leukemia Drug Price

Brainstorm Health Daily: August 23, 2017 Good morning, readers! This is Sy. A new study making the rounds suggests that high intake of B vitamins is associated with an increased risk for lung cancer. Let’s look beyond.....»»

Category: europeSource: fortuneAug 23rd, 2017

AstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment

InvestorPlace - Stock Market News, Stock Advice & Tradi.....»»

Category: topSource: investorplaceJul 27th, 2017

AstraZeneca Shares Dive After Major Setback Over Cancer Drugs

AstraZeneca said a combination of two of its new oncology drugs failed to shrink lung cancer tumors in a clinical trial, casting doubt on a central part of its ambitious growth plans. Shares fell 16%......»»

Category: smallbizSource: wsjJul 27th, 2017

Shares in AstraZeneca dive as key cancer drug trial fails

AstraZeneca said human trials of the drug Imfinzi failed to meet the goal of improving progression-free survival rates in patients with non-small cell lung cancer. &.....»»

Category: topSource: usatodayJul 27th, 2017

AstraZeneca plunges 16% after its lung cancer drug failed a key trial (AZN)

Markets InsiderLONDON, July 27 (Reuters) - AstraZeneca's .....»»

Category: topSource: businessinsiderJul 27th, 2017